Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Payables (2016 - 2025)

Cytosorbents (CTSO) has disclosed Payables for 14 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 29.8% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Sep 2025, up 29.8%, and an annual FY2024 reading of $3.3 million, down 12.16% over the prior year.
  • Payables was $3.0 million for Q3 2025 at Cytosorbents, down from $3.4 million in the prior quarter.
  • Across five years, Payables topped out at $4.8 million in Q1 2022 and bottomed at $1.7 million in Q4 2022.
  • Average Payables over 5 years is $2.9 million, with a median of $3.0 million recorded in 2023.
  • Peak annual rise in Payables hit 187.66% in 2022, while the deepest fall reached 41.0% in 2022.
  • Year by year, Payables stood at $2.8 million in 2021, then tumbled by 41.0% to $1.7 million in 2022, then skyrocketed by 129.71% to $3.8 million in 2023, then fell by 12.16% to $3.3 million in 2024, then fell by 9.13% to $3.0 million in 2025.
  • Business Quant data shows Payables for CTSO at $3.0 million in Q3 2025, $3.4 million in Q2 2025, and $3.3 million in Q1 2025.